Tonix Pharmaceuticals Announces PDUFA Goal Date Of August 15, 2025, For FDA Decision On U.S. Marketing Approval For TNX-102 SL For Fibromyalgia; NDA Based On Two Statistically Significant Phase 3 Studies Of TNX-102 SL For The Management Of Fibromyalgia, In Which TNX-102 SL Was Generally Well Tolerated
Tonix received FDA's Day 74 Letter granting TNX-102 SL a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025
TNX-102 SL is a non-opioid, centrally acting analgesic, granted Fast Track designation by FDA
Fibromyalgia affects more than 10 million adults in the U.S., who are mostly women
TNX-102 SL has the potential to be the first member of a new class of analgesic drugs for fibromyalgia and first new drug for its treatment in more than 15 years
NDA based on two statistically significant Phase 3 studies of TNX-102 SL for the management of fibromyalgia, in which TNX-102 SL was generally well tolerated
CHATHAM, N.J., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) (Tonix or the Company) today announced that the U.S. Food and Drug Administration (FDA) assigned a Prescription Drug User Fee Act (PDUFA) goal date of August 15, 2025, for a decision on marketing approval for TNX-102 SL (cyclobenzaprine HCl sublingual tablets) for fibromyalgia. TNX-102 SL is a non-opioid, centrally-acting analgesic. Fibromyalgia is a common chronic pain condition that affects mostly women.
Tonix Pharmaceuticals宣布,FDA对于TNX-102 SL治疗纤维肌痛的美国市场批准的PDUFA目标日期为2025年8月15日;NDA基于两项统计学上显著的TNX-102 SL的第3阶段研究,TNX-102 SL通常耐受良好
Tonix收到了FDA的第74天函件,授予TNX-102 SL一个PDUFA目标日期为2025年8月15日
TNX-102 SL是一种非阿片类,中央作用的镇痛药,已获得FDA的快速通道认证
纤维肌痛在美国影响超过1000万成年人,主要是女性
TNX-102 SL有潜力成为治疗纤维肌痛新类别镇痛药的首位成员,也是15年来首个用于该病治疗的新药
NDA基于两项统计学上显著的TNX-102 SL的第3阶段研究,TNX-102 SL通常耐受良好
新泽西州查塔姆,2024年12月23日(环球新闻通讯社)-- Tonix Pharmaceuticals Holding Corp.(纳斯达克:TNXP)(Tonix或公司)今日宣布,美国食品和药物管理局(FDA)为TNX-102 SL(盐酸环抱扑林舌下片)在纤维肌痛上的市场批准决定分配了2025年8月15日的PDUFA目标日期。TNX-102 SL是一种非阿片类、中央作用的镇痛药。纤维肌痛是一种影响主要是女性的常见慢性疼痛控件。